Protagenic Therapeutics, Inc.\new Legal Fees
Protagenic Therapeutics, Inc.\new (PTIX) reported Legal Fees of $75.98 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LegalFees · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new legal fees for the quarter ending 2026-06-30 was $75.98K, a 62.89% decline year-over-year.
- Protagenic Therapeutics, Inc.\new legal fees for the quarter ending 2026-03-31 was $327.61K.
- Protagenic Therapeutics, Inc.\new legal fees for the quarter ending 2025-12-31 was $220.18K, a 565.27% increase year-over-year.
- Protagenic Therapeutics, Inc.\new legal fees for the quarter ending 2025-09-30 was $121.87K, a 57.20% increase year-over-year.
- Protagenic Therapeutics, Inc.\new legal fees for fiscal 2026 was $874.39K, a 377.56% increase from fiscal 2025.
- Protagenic Therapeutics, Inc.\new legal fees for fiscal 2025 was $183.10K.
| Period end | Legal Fees 3 month | Legal Fees 6 month | Legal Fees 9 month | Legal Fees 12 month |
|---|---|---|---|---|
| 2026-06-30 | $75.98K 10-Q · filed 2026-08-19 | $403.59K derived: sum of 2 quarters · filed 2026-08-19 | $623.77K derived: sum of 3 quarters · filed 2026-08-19 | $745.64K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $327.61K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $547.79K derived: sum of 2 quarters · filed 2026-08-14 | $669.66K derived: sum of 3 quarters · filed 2026-08-14 | $874.39K 10-K · filed 2026-08-14 |
| 2025-12-31 | $220.18K 10-Q · filed 2026-03-09 | $342.05K derived: sum of 2 quarters · filed 2026-03-09 | $546.78K 10-Q · filed 2026-03-09 | $546.76K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-09-30 | $121.87K 10-Q · filed 2025-11-26 | $326.60K 10-Q · filed 2025-11-26 | $326.58K derived: sum of 3 quarters · filed 2026-08-19 | $359.67K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $204.73K 10-Q · filed 2026-08-19 | $204.71K derived: sum of 2 quarters · filed 2026-08-19 | $237.81K derived: sum of 3 quarters · filed 2026-08-19 | $315.33K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$25.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $33.07K derived: sum of 2 quarters · filed 2026-08-14 | $110.60K derived: sum of 3 quarters · filed 2026-08-14 | $183.10K 10-K · filed 2026-08-14 |
| 2024-12-31 | $33.10K 10-Q · filed 2026-03-09 | $110.62K derived: sum of 2 quarters · filed 2026-03-09 | $183.12K 10-Q · filed 2026-03-09 | |
| 2024-09-30 | $77.53K 10-Q · filed 2025-11-26 | $150.03K 10-Q · filed 2025-11-26 | ||
| 2024-06-30 | $72.50K 10-QT · filed 2025-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |